Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14% |
| Mar 31, 2026 | -4.24% |
| Dec 31, 2025 | -51.99% |
| Sep 30, 2025 | -30.43% |
| Jun 30, 2025 | 21.79% |
| Mar 31, 2025 | 15.60% |
| Dec 31, 2024 | -13.89% |
| Sep 30, 2024 | 16.66% |
| Jun 30, 2024 | -3.89% |
| Mar 31, 2024 | -5.42% |
| Dec 31, 2023 | -1.55% |
| Sep 30, 2023 | -25.06% |
| Jun 30, 2023 | -1.12% |
| Mar 31, 2023 | -19.69% |
| Dec 31, 2022 | 24.62% |
| Sep 30, 2022 | -42.81% |
| Jun 30, 2022 | -39.35% |
| Mar 31, 2022 | -42.52% |
| Dec 31, 2021 | -13.66% |
| Sep 30, 2021 | -23.97% |